Abstract
A series of new C-3 and N1-substituted 4-fluorotryptamides have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. Planar sp2 geometry at C-3-βC seems to decrease the population of the preferred conformation as it renders 4-fluoroindoles 4b-d weaker antagonists than their C-3-βC-unsubstituted congeners 3a-e. This effect is not preclusively linked with the C-3 region, as the same geometry around N1 (compounds 5a-c) similarly leads to weak antagonistic action. Last, the new C-3 substituted 4-fluorotryptamides presented herein are substantially more potent than their respective N-OMe functionalized congeners, previously reported.
Keywords: Substituted 4-fluoroindoles, synthesis, melatoninergic activity
Current Drug Discovery Technologies
Title: Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics
Volume: 4 Issue: 3
Author(s): Andrew Tsotinis, Andreas Eleutheriades, Kathryn Davidson, David Sugden, Andrew Tsotinis, Andreas Eleutheriades, Kathryn Davidson and David Sugden
Affiliation:
Keywords: Substituted 4-fluoroindoles, synthesis, melatoninergic activity
Abstract: A series of new C-3 and N1-substituted 4-fluorotryptamides have been prepared and tested for their ability to activate pigment granule aggregation in Xenopus laevis melanophores and bind to the recombinant human MT1 and MT2 melatonin receptor subtypes expressed in NIH 3T3 cells. Planar sp2 geometry at C-3-βC seems to decrease the population of the preferred conformation as it renders 4-fluoroindoles 4b-d weaker antagonists than their C-3-βC-unsubstituted congeners 3a-e. This effect is not preclusively linked with the C-3 region, as the same geometry around N1 (compounds 5a-c) similarly leads to weak antagonistic action. Last, the new C-3 substituted 4-fluorotryptamides presented herein are substantially more potent than their respective N-OMe functionalized congeners, previously reported.
Export Options
About this article
Cite this article as:
Tsotinis Andrew, Eleutheriades Andreas, Davidson Kathryn, Sugden David, Tsotinis Andrew, Eleutheriades Andreas, Davidson Kathryn and Sugden David, Design and Synthesis of New N1 and C3-Substituted 4-Fluoroindolic Melatoninergics, Current Drug Discovery Technologies 2007; 4 (3) . https://dx.doi.org/10.2174/157016307782109715
DOI https://dx.doi.org/10.2174/157016307782109715 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Drug Delivery & Formulation Differentiating Normal from Pathological Brain Ageing Using Standard Neuropsychological Tests
Current Alzheimer Research Biological Roles of the Eclectic Chromogranin-A-derived Peptide Catestatin
Current Medicinal Chemistry Commentary: Hot, Hotter, and Hottest Trends in α-Synuclein Research
Current Protein & Peptide Science The Role of Renal Nerve Ablation for the Management of Resistant Hypertension and other Disease Conditions: Benefits and Concerns
Current Vascular Pharmacology Effects of Early Maternal Separation on Biobehavioral and Neuropathological Markers of Alzheimer's Disease in Adult Male Rats
Current Alzheimer Research Reversal of Calcium Dysregulation as Potential Approach for Treating Alzheimer's Disease
Current Alzheimer Research Metal-Protein Attenuating Compounds (MPACs) for the Treatment of Alzheimers Disease
Drug Design Reviews - Online (Discontinued) Stem Cells in Amyotrophic Lateral Sclerosis: Motor Neuron Protection or Replacement?
CNS & Neurological Disorders - Drug Targets The Multiple Roles of Vitamin D in Human Health. A Mini-Review
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Whole body vibration training improves walking performance of stroke patients with knee hyperextension: a randomized controlled pilot study
CNS & Neurological Disorders - Drug Targets PET Radiotracers for Molecular Imaging in Dementia
Current Radiopharmaceuticals The Potential Health Benefits of Algae and Micro Algae in Medicine: A Review on Spirulina platensis
Current Nutrition & Food Science Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease
Mini-Reviews in Medicinal Chemistry Gender-Dependent Levels of Hyaluronic Acid in Cerebrospinal Fluid of Patients with Neurodegenerative Dementia
Current Alzheimer Research Subject Index to Volume 3
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease
Current Signal Transduction Therapy Candidate Circulating Biomarkers for the Cardiovascular Disease Continuum
Current Pharmaceutical Design Brain Network Connectivity Mediates Education-related Cognitive Performance in Healthy Elderly Adults
Current Alzheimer Research Dual Effects of Antioxidants in Neurodegeneration: Direct Neuroprotection against Oxidative Stress and Indirect Protection via Suppression of Gliamediated Inflammation
Current Pharmaceutical Design